A molecule is shown to produce cognitive improvement in rodents with early Alzheimer’s disease

The UPV/EHU’s Neurochemistry and Neurodegeneration group has come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents.

Clarifying the cause of Guillain-Barré Syndrome

Patients with Guillain-​Barré syndrome (GBS) face a rare and heterogeneous disorder of the peripheral nervous system that is often triggered by preceding infections and causes severe muscle weakness. In Europe

First successful clinical trial of VU319 brings Alzheimer’s treatment one step closer

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a